Medical Companies

Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology
Trigen previously announced the successful completion of a Phase I dose escalation study on TGN 167 using a classical rapid release tablet formulation. Trigen is developing TGN 167 for safe, effective, predictable and convenient anticoagulation for chronic out-patient use in the prevention and treatment of thrombosis. Trigen is a private UK biotechnology company, based in London, that discovers and develops novel drugs for the management of occlusive and inflammatory cardiovascular diseases. Trigen’s lead programme, comprising a series of anticoagulant direct thrombin inhibitors (DTIs) for the prevention and treatment of thrombosis, is in clinical development in both intravenous and oral ( www.trigen.co.uk )

Trigen Ltd
Clareville House 26-27 Oxendon Street
London SW1Y 4EL
United Kingdom

Tel: +44 20 7004 2630
Fax: +44 20 7004 2631

Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology
The Company is committed to continuing its development as a niche oncology product company. The relatively shorter development time for its niche product candidates, e.g. SaveneTM and SavicolTM, will, if approved for commercialisation, allow TopoTarget to establish relationships with oncology clinics and to build European sales and marketing capabilities at an early stage. This potential early entry of niche products on the market is expected to facilitate any future introductions of other product candidates. To expedite development of product candidates with potential broad applications, TopoTarget will seek collaborations with partners to assist in clinical matters, such as in patient recruitment, and in commercial matters, such as in providing geographic ( www.topotarget.com )

TopoTarget
87A Milton Park
Abingdon, Oxfordshire OX14 4RY
United Kingdom

Tel: +44 1235 443 700
Fax: +44 1235 835 557

Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology
Renovo is a biopharmaceutical product company and is the world leader in scar prevention and reduction research, and the development of drugs to prevent and reduce scarring. The Company has a highly skilled management team with over 30 years of research in the field of scarring, and significant pharmaceutical industry experience. Renovo has a portfolio of drugs which exploit different novel mechanisms of action to prevent and reduce scarring at multiple body sites and to accelerate healing. The Company’s deep pipeline includes four drugs in phase II clinical development, a further four advanced pre-clinical candidates and nine other pre-clinical ( www.renovo.com )

Renovo Ltd
The Manchester Incubator Building 48 Grafton Street
Manchester, M13 9XX
United Kingdom

Tel: +44 161 606 7328
Fax: +44 161 606 7333

Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology
Vernalis is a speciality bio-pharmaceutical company focused on products marketed to specialist neurologists. The company has two marketed products, Frova® and Apokyn®, and a development pipeline focused on neurology and central nervous system disorders. The company has eight products in clinical development and collaborations with leading, global pharmaceutical companies including Novartis, Biogen Idec and Serono. Vernalis has established a US commercial operation to promote Apokyn® and co-promote Frova® alongside its North American licensing partner, Endo Pharmaceuticals, progressing the company towards its goal of becoming a sustainable, self-funding, R&D-driven, speciality bio-pharmaceutical company. ( www.vernalis.com )

Vernalis plc
Oakdene Court 613 Reading Road
Winnersh, BERKSHIRE RG41 5UA
United Kingdom

Tel: +44 118 977 3133
Fax: +44 118 989 9300

Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology
VASTox is a chemical genomics technology company that provides services to the pharmaceutical industry and discovers and develops proprietary novel drugs. The company’s technology platform aims to use high volume, high content screening using zebrafish and fruitflies to provide a high level of predictability of the efficacy and toxicity of potential drug compounds in humans which has the potential to dramatically decrease the time and cost of drug discovery and development. VASTox was formed in January 2003, from the University of Oxford, by some of the UK’s foremost scientists who have taken a highly creative approach to the problems involved in drug discovery and who have a proven record in delivering technological ( www.vastox.com )

VASTox plc
Vastox 91 Milton Park
Abingdon, Oxfordshire OX14 4RY
United Kingdom

Tel: +44 1235 443903

Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology
CeNeS Pharmaceuticals plc (AIM: CEN), the biopharmaceutical company developing a new generation of pain management products, announces interim results for the six months ended 30 June 2006. In a separate announcement made today, CeNeS gives a more detailed update on its lead product for post-operative pain, M6G. ( www.cenes.com )

CeNeS Pharmaceuticals plc
Compass House, Vision Park Chivers Way, Histon
Cambridge, CB24 9ZR
United Kingdom

Tel: +44 1223 266466
Fax: +44 1223 266467

Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology
Oxagen is focused on becoming a significant biopharmaceutical company, developing a pipeline of novel drugs to treat inflammatory diseases. The Company has created a portfolio of valuable drug targets centered on the highly attractive class of receptors, GPCRs. Through its heritage in human genetics, Oxagen has validated a number of GPCR targets, many of them novel, and selected the most promising as drug targets. Oxagen was established in April 1997 and initially focused on identifying drug targets through genetics. Since 2003 the Company has focused on building a drug discovery and development capability and pipeline around GPCR targets. The Company is based in Milton Park, south of Oxford. ( www.oxagen.co.uk )

Oxagen Limited
91 Milton Park
Abingdon, Oxfordshire OX14 4RY
United Kingdom

Tel: +44 1235 443300
Fax: +44 1235 443301

Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology
Protherics is a leading biopharmaceutical company focused on developing, manufacturing and marketing critical care and cancer products. We have developed two FDA approved products in-house, CroFabÔ and DigiFabÔ. Our plan is to use revenues from our marketed products and licensing income to help fund the development of a robust and high value pipeline of products. We seek to use industry collaborations and M&A to achieve our goals in an industry where critical mass is needed to achieve long-term growth. In December 2006, we announced a ,38.2 million fundraising and the signing of three key agreements to expand our development ( www.protherics.com )

Protherics PLC
The Heath Business And Technical Park
Runcorn, CHESHIRE WA7 4QF
United Kingdom

Tel: +44 1928 518000
Fax: +44 1928 518002